What is CORE Diagnostics?
CORE Diagnostics stands as a premier diagnostic center and pathology laboratory network within India. The company offers an extensive suite of diagnostic tests and procedures, with a particular emphasis on advanced diagnostics for critical medical conditions such as cancer, inherited diseases, and reproductive health. Leveraging cutting-edge technologies in molecular biology, immunohistochemistry, and cytopathology, CORE Diagnostics is committed to delivering precise and dependable diagnostic results. Their services are designed to support healthcare professionals and patients alike, providing innovative and accessible solutions aimed at enhancing clinical outcomes and patient care.
How much funding has CORE Diagnostics raised?
CORE Diagnostics has raised a total of $17.3M across 2 funding rounds:
Series A
$5M
Series B
$12.3M
Series A (2012): $5M with participation from Artiman Ventures
Series B (2016): $12.3M led by F-Prime Capital Partners, Artiman Ventures, and Eight Roads Ventures
Key Investors in CORE Diagnostics
F-Prime Capital Partners
F-Prime Capital Partners is a venture capital firm established in 2002, focusing on investments in healthcare and technology sectors. They support innovative companies with a team of investors, engineers, doctors, and scientists, aiming to drive advancements in health and technology.
Artiman Ventures
Artiman Ventures is an investment firm that backs innovative companies across various sectors, including healthcare, technology, and education. They have a track record of investing in companies focused on AI, diagnostics, and application security.
Eight Roads Ventures
Eight Roads Ventures is a global investment firm that backs ambitious entrepreneurs and companies. They focus on sectors such as technology, healthcare, and financial services, providing long-term capital and strategic support.
What's next for CORE Diagnostics?
With the recent major strategic investment, CORE Diagnostics is poised for significant expansion and technological advancement. The company is expected to further enhance its high-end diagnostic capabilities, potentially broadening its service offerings in molecular biology and precision medicine. This capital injection will likely fuel strategic initiatives, including the scaling of operations across India, adoption of new diagnostic technologies, and strengthening of its research and development efforts. The focus will remain on providing reliable and accessible diagnostic solutions, reinforcing its leadership in the Indian healthcare landscape and improving patient outcomes through advanced pathology and laboratory services.
See full CORE Diagnostics company page
